F S&P 500
5,118.00 +35.75 (+0.70%) F Dow Jones
38,322.00 +34.00 (+0.09%) F Nasdaq
17,734.50 +167.00 (+0.95%) E-mini Russell 2000 Index Futur
1,992.50 -0.70 (-0.04%) Petróleo
84.38 +0.81 (+0.97%) Oro
2,357.20 +14.70 (+0.63%)
Mithra Pharmaceuticals SA (MITRA.BR)
Mithra Pharmaceuticals SA
Rue Saint-Georges 5
Liège 4000
Belgium
32 4 349 28 22
https://www.mithra.com
Sector(es): Healthcare
Industria: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Christophe Marechal | Co-CEO & CFO | N/D | N/D | N/D |
| Mr. Xavier Paoli M.Sc. | COO & Co-CEO | N/D | N/D | N/D |
| Dr. Graham K. Dixon Ph.D. | Chief Scientific Officer | N/D | N/D | 1961 |
| Mr. Alex Sokolowski | Head of Investor Relations | N/D | N/D | N/D |
| Fanny Rozenberg | Secretary of the Board & General Counsel | N/D | N/D | N/D |
| Fanny Storms | Compliance Officer | N/D | N/D | N/D |
| Mr. Frederique Depraetere | Communication Director | N/D | N/D | N/D |
| Ms. Catherine Lejeune | HR Director | N/D | N/D | N/D |
| Mr. Jean-Manuel Fontaine | Chief Commercial & External Affairs Officer | N/D | N/D | N/D |
| Prof. Jean-Michel Foidart M.D., Ph.D. | President of the Scientific Advisory Board & Executive Director | 7.12k | N/D | N/D |
Descripción
Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally. Its development candidates include Estelle, a combined oral contraceptive that has completed phase III clinical trial; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment; and products for neuroprotection and wound healing. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a tablet composed of tibolone and a synthetic steroid used for hormone therapy in menopause; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. The company was founded in 1999 and is headquartered in Liège, Belgium.
Gestión corporativa
La calificación ISS Governance QuickScore de Mithra Pharmaceuticals SA a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
